Rigel Pharmaceuticals (RIGL) Common Equity (2010 - 2026)

Rigel Pharmaceuticals' Common Equity history runs 17 years deep, the most recent figure standing at $399.9 million for Q1 2026.

• On a quarterly basis, Common Equity rose 2053.81% year-over-year to $399.9 million in Q1 2026; TTM through Mar 2026 was $399.9 million, a 2053.81% increase from a year earlier, with the FY2025 full-year figure at $391.5 million, up 11806.33% from the prior year.
• Common Equity improved to $399.9 million in Q1 2026 per RIGL's latest filing, from $391.5 million in the prior quarter.
• Across five years, Common Equity topped out at $399.9 million in Q1 2026 and bottomed at -$31.8 million in Q3 2023.
• The 5-year median for Common Equity is -$13.6 million (2022), against an average of $46.7 million.
• Across the five-year window, Common Equity sank 664.62% in 2023 and jumped 11806.33% in 2025, its largest moves.
• Year by year, Common Equity stood at -$13.6 million in 2022, then sank by 110.37% to -$28.6 million in 2023, then surged by 111.48% to $3.3 million in 2024, then soared by 11806.33% to $391.5 million in 2025, then gained by 2.15% to $399.9 million in 2026.
• Per Business Quant, the three latest RIGL Common Equity figures stand at $399.9 million (Q1 2026), $391.5 million (Q4 2025), and $117.6 million (Q3 2025).